2-(2-Chloro-4-methoxyphenyl)-1,3-thiazole-5-carbaldehyde | 960605-20-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(2-Chloro-4-methoxyphenyl)-1,3-thiazole-5-carbaldehyde
• CAS: 960605-20-3
• 化学式: C₁₁H₈ClNO₂S
• 分子量: 253.709
• InChiKey: SGSNKZQSDMGYGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-Chloro-4-methoxyphenyl)-1,3-thiazole-5-carbaldehyde 、 三甲基膦酰基乙酸酯 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.5h， 生成 methyl (E)-3-[2-(2-chloro-4-methoxyphenyl)-1,3-thiazol-5-yl]prop-2-enoate
  参考文献：
  名称：

  Discovery of Biaryl Anthranilides as Full Agonists for the High Affinity Niacin Receptor

  摘要：

  Biaryl anthranilides are reported as potent and selective full agonists for the high affinity niacin receptor GPR109A. The SAR presented outlines approaches to reduce serum shift and both CYPCYP2C8 and CYP2C9 liabilities, while improving PK and maintaining excellent receptor activity. Compound 2i exhibited good in vivo antilipolytic efficacy while providing a significantly improved therapeutic index over vasodilation (flushing) with respect to niacin in the mouse model.

  DOI：

  10.1021/jm700942d
• 作为产物：
  描述：

  2-溴-5-甲醛基噻唑 、 2-氯-4-甲氧基苯硼酸 在 四(三苯基膦)钯 碳酸氢钠 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 生成 2-(2-Chloro-4-methoxyphenyl)-1,3-thiazole-5-carbaldehyde
  参考文献：
  名称：

  Discovery of Biaryl Anthranilides as Full Agonists for the High Affinity Niacin Receptor

  摘要：

  Biaryl anthranilides are reported as potent and selective full agonists for the high affinity niacin receptor GPR109A. The SAR presented outlines approaches to reduce serum shift and both CYPCYP2C8 and CYP2C9 liabilities, while improving PK and maintaining excellent receptor activity. Compound 2i exhibited good in vivo antilipolytic efficacy while providing a significantly improved therapeutic index over vasodilation (flushing) with respect to niacin in the mouse model.

  DOI：

  10.1021/jm700942d

文献信息

• Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
  申请人：Colletti L. Steven

  公开号：US20070281969A1

  公开（公告）日：2007-12-06

  The present invention encompasses compounds of Formula (I); as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖了式（I）的化合物；以及其药学上可接受的盐和水合物，可用于治疗血脂异常。还包括制药组合物和使用方法。
• WO2006/57922
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery of Biaryl Anthranilides as Full Agonists for the High Affinity Niacin Receptor
  作者：Hong C. Shen、Fa-Xiang Ding、Silvi Luell、Michael J. Forrest、Ester Carballo-Jane、Kenneth K. Wu、Tsuei-Ju Wu、Kang Cheng、Larissa C. Wilsie、Mihajlo L. Krsmanovic、Andrew K. Taggart、Ning Ren、Tian-Quan Cai、Qiaolin Deng、Qing Chen、Junying Wang、Michael S. Wolff、Xinchun Tong、Tom G. Holt、M. Gerard Waters、Milton L. Hammond、James R. Tata、Steven L. Colletti

  DOI：10.1021/jm700942d

  日期：2007.12.13

  Biaryl anthranilides are reported as potent and selective full agonists for the high affinity niacin receptor GPR109A. The SAR presented outlines approaches to reduce serum shift and both CYPCYP2C8 and CYP2C9 liabilities, while improving PK and maintaining excellent receptor activity. Compound 2i exhibited good in vivo antilipolytic efficacy while providing a significantly improved therapeutic index over vasodilation (flushing) with respect to niacin in the mouse model.